MEK and the inhibitors: from bench to bedside

被引：0
|
作者：
Akintunde Akinleye
Muhammad Furqan
Nikhil Mukhi
Pavan Ravella
Delong Liu
机构：
[1] Westchester Medical Center and New York Medical College,Department of Medicine
[2] New York Medical College and Westchester Medical Center,Division of Hematology and Oncology
来源：
Journal of Hematology & Oncology | / 6卷
关键词：
Melanoma; Docetaxel; Papillary Thyroid Cancer; Malignant Mesothelioma; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.
引用
收藏
相关论文
共 50 条
  • [1] MEK and the inhibitors: from bench to bedside
    Akinleye, Akintunde
    Furqan, Muhammad
    Mukhi, Nikhil
    Ravella, Pavan
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [2] A review of PARP inhibitors: from bench to bedside
    Underhill, C.
    Toulmonde, M.
    Bonnefoi, H.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 268 - 279
  • [3] MET inhibitors: translating from bench to bedside
    Mayor, Susan
    LANCET ONCOLOGY, 2011, 12 (01): : 14 - 14
  • [4] Aromatase inhibitors: from bench to bedside and back
    Geisler, Jurgen
    BREAST CANCER, 2008, 15 (01) : 17 - 26
  • [5] Rapamycine and mTOR inhibitors: from bench to bedside
    Pallet, N.
    Beaune, P.
    Legendre, C.
    Anglicheau, D.
    ANNALES DE BIOLOGIE CLINIQUE, 2006, 64 (02) : 107 - 115
  • [6] RTK Inhibitors in Melanoma: From Bench to Bedside
    Sabbah, Malak
    Najem, Ahmad
    Krayem, Mohammad
    Awada, Ahmad
    Journe, Fabrice
    Ghanem, Ghanem E.
    CANCERS, 2021, 13 (07)
  • [7] Aromatase inhibitors: from bench to bedside and back
    Jürgen Geisler
    Breast Cancer, 2008, 15 : 17 - 26
  • [8] GPIIb/IIIa inhibitors: From bench to bedside and back to bench again
    Armstrong, Paul C.
    Peter, Karlheinz
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 808 - 814
  • [9] From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors
    Gardner, Christopher R.
    Davies, Katherine A.
    Zhang, Ying
    Brzozowski, Martin
    Czabotar, Peter E.
    Murphy, James M.
    Lessene, Guillaume
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (04) : 2361 - 2385
  • [10] B-Raf and the inhibitors: from bench to bedside
    Tiangui Huang
    Michael Karsy
    Jian Zhuge
    Minghao Zhong
    Delong Liu
    Journal of Hematology & Oncology, 6
12345